Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug312 | Anti-Sars-CoV-2 Convalescent Plasma Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The health crisis imposed by COVID-19 is forcing major worldwide social reorganization that will have profound consequences on our society. Currently, one-third of the world's population (~3 billion individuals) is living under some kind of isolation or quarantine measures, causing an unprecedented and rapidly evolving psychosocial crisis. The psychosocial consequences of this health crisis will persist long after restriction measures are lifted and the pandemic is over. This impact will be significant for individuals facing unique contexts or challenges (e.g., older adults, individuals living with a disability, underprivileged families) and will most likely exacerbate existing social and gender inequalities in health and human development. There is an urgent need for information on the evolution of the psychosocial dimensions of health and coping strategies used by our population and our health and social services structures. Thus, this study is designed to accelerate the availability of high-quality, real-time evidence within health and social services structures to address, support and minimize psychosocial consequences of the COVID-19 pandemic. Through constantly evolving research questions responsive to the course of the pandemic evolution, the rapid system transformations and adaptation of services, and knowledge users (KUs) needs, MAVIPAN aims to address, document, monitor, and evaluate the following: 1. Individuals and families' adjustments and mitigation strategies, especially for those considered vulnerable and in high-risk contexts. 2. Healthcare and social services workers and managers' adjustments and mitigation strategies. 3. The organization of service structures. 4. The social and economic response. To achieve these objectives, we use a mixed methods study design that combines quantitative questionnaires and qualitative interviews to deepen our understanding of elements such as the coping strategies used during the pandemic. A first measure was taken during lock-down as well as a follow-up at 3 months. Another follow-up will be made at 7 months. At least one per year follow-up will be made over the course of the study (5 years). Additional measures may be taken depending on the evolution of the pandemic and the sanitary measures put in place by the authorities.
Description: The DASS-21 is a measure of depression, anxiety and stress symptoms. The score on each subscale varies from 0 to 21. A higher score means a higher level of symptoms.
Measure: Depression, Anxiety and Stress Scale-21 (DASS-21) Time: Baseline (measured during lockdown in March 2020)Description: The DASS-21 is a measure of depression, anxiety and stress symptoms. The score on each subscale varies from 0 to 21. A higher score means a higher level of symptoms.
Measure: Depression, Anxiety and Stress Scale-21 (DASS-21) Time: 3 monthsDescription: The DASS-21 is a measure of depression, anxiety and stress symptoms. The score on each subscale varies from 0 to 21. A higher score means a higher level of symptoms.
Measure: Depression, Anxiety and Stress Scale-21 (DASS-21) Time: 7 monthsDescription: Scores vary between 0 and 28. A higher score means greater insomnia severity.
Measure: Insomnia Severity Index Time: Baseline (measured during lockdown in March 2020)Description: Scores vary between 0 and 28. A higher score means greater insomnia severity.
Measure: Insomnia Severity Index Time: 3 monthsDescription: Scores vary between 0 and 28. A higher score means greater insomnia severity.
Measure: Insomnia Severity Index Time: 7 monthsDescription: Scores range from 7 to 35 and higher scores indicate higher positive well-being.
Measure: Warwick-Edinburgh Mental Well-Being Scale Time: Baseline (measured during lockdown in March 2020)Description: Scores range from 7 to 35 and higher scores indicate higher positive well-being.
Measure: Warwick-Edinburgh Mental Well-Being Scale Time: 3 monthsDescription: Scores range from 7 to 35 and higher scores indicate higher positive well-being.
Measure: Warwick-Edinburgh Mental Well-Being Scale Time: 7 monthsDescription: Only the Hostility subscale that measures thoughts, feelings and actions characteristic of anger is used. Scores range from 6 to 24 and higher scores indicate higher level of hostility
Measure: Hostility subscale- Symptoms Checklist-90-Revised Time: Baseline (measured during lockdown in March 2020)Description: Only the Hostility subscale that measures thoughts, feelings and actions characteristic of anger is used. Scores range from 6 to 24 and higher scores indicate higher level of hostility
Measure: Hostility subscale- Symptoms Checklist-90-Revised Time: 3 monthsDescription: Only the Hostility subscale that measures thoughts, feelings and actions characteristic of anger is used. Scores range from 6 to 24 and higher scores indicate higher level of hostility
Measure: Hostility subscale- Symptoms Checklist-90-Revised Time: 7 monthsDescription: These are self-report questions that measure the change in consumption level of different substances such as alcool, prescriptions medications and illicit drugs prior and after the lockdown.
Measure: Substance use Time: Baseline (measured during lockdown in March 2020)Description: These are self-report questions that measure the change in consumption level of different substances such as alcool, prescriptions medications and illicit drugs prior and after the lockdown.
Measure: Substance use Time: 3 monthsDescription: These are self-report questions that measure the change in consumption level of different substances such as alcool, prescriptions medications and illicit drugs prior and after the lockdown.
Measure: Substance use Time: 7 monthsDescription: We use a subset of questions taken from the Brief Cope which measures coping strategies.
Measure: Brief COPE Time: Baseline (measured during lockdown in March 2020)Description: We use a subset of questions taken from the Dyadic Adjustment Scale which measures couple satisfaction.
Measure: Dyadic Adjustment Scale Time: Baseline (measured during lockdown in March 2020)Description: We only use the Interaction subscale which measures the extent to which the parent believes the child is not meeting expectations and finds interactions with the child are not reinforcing his parenting role.
Measure: Parental Stress Index Time: Baseline (measured during lockdown in March 2020)Description: We use a subset of questions that measures the presence of minor physical abuse as well as psychological abuse.
Measure: Child Conflict Tactic Scale Time: Baseline (measured during lockdown in March 2020)Description: We use a subset of questions that aim to measure different child behaviors and personality caracteristics.
Measure: Strengths and Difficulties Questionnaire Time: Baseline (measured during lockdown in March 2020)Description: We use a series of questions that assess different changes that may have occured in their work, as well as a series of beliefs they may hold concerning their work and their patients/clients.
Measure: Healthcare workers adaptation Time: Baseline (measured during lockdown in March 2020)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports